Identification Et Régulation Transcriptionnelle Des Gènes

Total Page:16

File Type:pdf, Size:1020Kb

Identification Et Régulation Transcriptionnelle Des Gènes Identification et Régulation 277 Transcriptionnelle des Gènes Cibles du Récepteur Minéralocorticoïde dans les Cellules Rénales : 2017SACLS NNT Thèse de doctorat de l'Université Paris-Saclay préparée à l’Université Paris-Sud École doctorale n°568 Signalisation et Réseaux Intégratifs en Biologie (Biosigne) Spécialité de doctorat : Aspects Moléculaires et Cellulaires de la Biologie Thèse présentée et soutenue à Le Kremlin-Bicêtre, le 6 Octobre 2017, par Florian LE BILLAN Composition du Jury : Madame la Dr Pascale CHAVATTE-PALMER DR INRA-ENVA, INRA Jouy-en-Josas Président Madame la Dr Morgane THOMAS-CHOLLIER MCU, École Normale Supérieure de Paris Rapporteur Monsieur le Dr Antoine OUVRARD-PASCAUD MCU, Université de Rouen Rapporteur Monsieur le Dr Vincent CAVAILLÈS DR Inserm, Université de Montpellier Examinateur Monsieur le Dr Marc LOMBÈS DR Inserm, Université Paris-Sud Directeur de thèse Monsieur le Dr Jérôme FAGART CR Inserm, Université Paris-Sud Co-Directeur de thèse Identification et Régulation 277 Transcriptionnelle des Gènes Cibles du Récepteur Minéralocorticoïde dans les Cellules Rénales : 2017SACLS NNT Thèse de doctorat de l'Université Paris-Saclay préparée à l’Université Paris-Sud École doctorale n°568 Signalisation et Réseaux Intégratifs en Biologie (Biosigne) Spécialité de doctorat : Aspects Moléculaires et Cellulaires de la Biologie Thèse présentée et soutenue à Le Kremlin-Bicêtre, le 6 Octobre 2017, par Florian LE BILLAN Composition du Jury : Madame la Dr Pascale CHAVATTE-PALMER DR INRA-ENVA, INRA Jouy-en-Josas Président Madame la Dr Morgane THOMAS-CHOLLIER MCU, École Normale Supérieure de Paris Rapporteur Monsieur le Dr Antoine OUVRARD-PASCAUD MCU, Université de Rouen Rapporteur Monsieur le Dr Vincent CAVAILLÈS DR Inserm, Université de Montpellier Examinateur Monsieur le Dr Marc LOMBÈS DR Inserm, Université Paris-Sud Directeur de thèse Monsieur le Dr Jérôme FAGART CR Inserm, Université Paris-Sud Co-Directeur de thèse Remerciements Ce travail de Thèse a été rendu possible grâce à la participation et au soutien de nombreuses personnes que je tenais à remercier ici. Je remercie les membres du jury d’avoir accepté d’évaluer mon travail de Thèse : Madame le Docteur Morgane Thomas-Chollier et monsieur le Docteur Antoine Ouvrard- Pascaud, je vous remercie plus particulièrement d’avoir pris le temps de lire mon manuscrit de Thèse, d’avoir évalué mon travail, et d’avoir partagé avec moi vos impressions et remarques. Madame le Docteur Pascale Chavatte-Palmer, je vous remercie de m’avoir fait l’honneur de présider mon jury de Thèse. Monsieur le Docteur Vincent Cavaillès, je vous remercie de m’avoir fait l’honneur d’être membre du jury en tant qu’examinateur. Je remercie monsieur le Docteur Laurent Sachs d’avoir suivi et soutenu ce projet au cours du Master et du Doctorat, notamment en y participant en tant qu’expert, au jury du comité de mi- parcours de Thèse. Je remercie également madame le Docteur Joëlle Cohen-Tannoudji d’avoir assumé le rôle de tutrice de Thèse. Vos conseils et suggestions m’ont été précieux. J’adresse ma plus profonde reconnaissance et mes plus sincères remerciements à mes Directeurs de Thèse, Marc et Jérôme. Marc, je te remercie de m’avoir accueilli dans ton équipe pour un stage de 1ère année de Master, et de m’avoir depuis permis de découvrir et d’intégrer le monde de la recherche scientifique. Je te remercie de m’avoir fait confiance en me proposant ce projet de Thèse et de m’avoir permis de le défendre au cours de congrès, notamment. J’admire le passionnant projet que tu as développé et la façon dont tu le mènes en t’entourant d’une solide et joyeuse équipe, et je te suis reconnaissant de m’avoir permis d’y apporter ma contribution. Je te remercie enfin pour tes conseils justes et avisés, ton encadrement constructif et bienveillant, ton soutien infaillible, pour tout le temps que tu m’as accordé, et pour le partage de ton immense savoir scientifique, théorique et pratique. Jérôme, je te remercie d’abord de m’avoir pris sous ton aile pour pouvoir poursuivre ce projet. Je te remercie pour ton encadrement quotidien impeccable, pour les moments inoubliables passés en L2 ou en chambre froide, pour nos conversations scientifiques très instructives et constructives, et pour tout ce que tu as fait pour ce manuscrit. Je te remercie surtout pour tes conseils et nos conversations plus personnelles qui ont contribué à construire notre belle complicité. Je ne saurais assez te remercier pour ton soutien constant et enthousiaste, et pour la confiance que tu m’as accordée. Junaid, je te remercie de m’avoir choisi pour t’accompagner dans le développement des expériences de ChIP, et de m’avoir appris une grande partie des approches que je maitrise aujourd’hui. C’est en partie grâce à toi que je suis entré dans l’Unité, et je t’en suis grandement reconnaissant. Je te remercie pour ta gentillesse, ta rigueur, ta patience et ton enthousiasme. Ce projet était aussi le tien, et j’espère que tu es fier de voir où je l’ai emmené. Je remercie chaleureusement l’ensemble des membres de l’Unité 1185 qui participent, chacun à leur manière, à la convivialité, à l’entraide et à l’ambiance de travail exceptionnelle qui y règne au quotidien. Say, tu es un des piliers centraux du laboratoire et ta présence a été indispensable à la bonne conduite de ce projet. Je te remercie pour ton aide quotidienne pour des conseils techniques, scientifiques, administratifs et personnels. En particulier, je te suis reconnaissant de m’avoir appris, avec rigueur, la culture cellulaire et la PCR quantitative, entre autres, mais aussi pour ta présence amicale à San Diego, ou encore ton aide pour mon ameublement. Je te remercie pour ta disponibilité et ton écoute qui m’ont été indispensables. Ton dévouement aux autres et à la science est pour moi exemplaire. Larbi, je te remercie pour ta grande générosité et ton énergie communicative. Je te remercie de m’avoir appris la microscopie à fluorescence et fait bénéficier de ton expertise en HTM, ce qui nous aura permis de réaliser deux beaux projets. Je te remercie pour nos conversations toujours intéressantes, tes conseils, scientifiques ou non, qui m’ont beaucoup aidé, et d’avoir partagé avec moi un pêché assumé : la gourmandise. Khadija, je te remercie pour ta gentillesse et pour le travail d’équipe que nous avons mené à bien, notamment grâce à ton énergie et à ta patience. Je repense à nos longs moments en L2 ou face à un certain sonicateur : ils ont été supportables grâce à ta bonne humeur et à nos rires. Damien, je te remercie pour ta gentillesse, ta disponibilité et ton aide, et pour toujours savoir partager ton expérience et animer les discussions. Et oui, ramener du fromage aux pots est une très bonne idée ! Stéphanie, je te remercie pour tes nombreux conseils judicieux, de m’avoir guidé en partageant ta propre expérience et pour ta gentillesse. Jérôme B, je te remercie de nous avoir aidés dans l’analyse bioinformatique des données de ChIP-Seq, avec Florian Nadal et Christophe Habib, et d’avoir toujours essayé de répondre aux questions que nous avions. Françoise, je te remercie pour ta gentillesse et ton naturel. Je te remercie aussi pour tes conseils, les services que tu m’as rendus et pour m’avoir fait découvrir de très bonnes musiques ! Géraldine, Mirella, Laurence, Thi An et Mohsen, je vous remercie pour votre grande gentillesse, votre bonne humeur quotidienne, votre générosité et votre amitié ! J’ai été heureux de partager mon passage dans l’Unité avec vous, je vous souhaite le meilleur pour la suite et fin de votre Thèse, j’ai confiance en vous ! Ingrid, je te suis reconnaissant pour tous les conseils que tu m’as donnés et tous les services rendus ! Suivre ton chemin au cours du Doctorat m’a permis de moins en appréhender les différentes épreuves. Je te remercie pour ta générosité et ton intégrité. Nathalie E, je te remercie pour ton énergie et ta spontanéité. J’ai été content de t’apprendre la technique de ChIP, certaines expressions françaises et de t’avoir eu comme copine de buffet ! Nadine, je te remercie pour tes nombreux conseils avisés et ta bienveillance. C’était un honneur de t’avoir comme marraine à la SFE ! Isabelle, je te remercie pour ta gentillesse, tes conseils et pour nos sympathiques covoiturages ! Justine, tu as été un exemple pour moi pour ta gentillesse, ta bienveillance, ton sens de l’organisation, ton sérieux et ta générosité ! Je te remercie de m’avoir montré toutes les astuces à connaitre pour un Western blot notamment, de m’avoir donné de bons conseils et de m’avoir aidé même une fois partie ! Valérie, je te remercie pour ta bonne humeur communicative ! C’était un plaisir de partager l’expérience du Doctorat avec toi, et le chocolat, et de pouvoir s’entraider ! Hui, 我很高兴认识你,并且和你分享这几年! 我希望你对法国的访问会让你幸福回忆,祝你未 来最好! Charlotte, je te remercie pour ta gentillesse et je te passe un double flambeau : tu es la prochaine à aller vivre à Antony, et surtout la prochaine à soutenir ! Même si je ne me fais pas de soucis pour toi, je te souhaite beaucoup de succès ! Laura, Clémence, Geoffrey, Paul, Nelly, Sophie, Vianney, Florent, Justine VdW, Adrien et Sara, c’était un plaisir de vous rencontrer et de partager votre passage au sein de l’Unité ! Je vous remercie tous pour votre gentillesse ! Mention spéciale pour Laura, ma copine de chocolat, pour Justine VdW et Adrien et leur don incontestable pour la cuisine, pour Nelly et Sophie pour leur diaporama de départ inoubliable, et pour Sara ma souriante camarade de master ! Christophe, je te remercie pour ton aide, ta sympathie et de m’avoir fait découvrir le Coq&Co ! Leïla, je te remercie chaleureusement pour ta grande gentillesse, ta bonne humeur, ton soutien et tes conseils.
Recommended publications
  • Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm
    Kidney360 Publish Ahead of Print, published on July 23, 2020 as doi:10.34067/KID.0000922020 Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm Michael R Lattanzio(1), Matthew R Weir(2) (1) Division of Nephrology, Department of Medicine, The Chester County Hospital/University of Pennsylvania Health System (2) Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD Correspondence: Matthew R Weir University of Maryland Medical Center Division of Nephrology 22 S. Greene St. Room N3W143 Baltimore, Maryland 21201 [email protected] 1 Copyright 2020 by American Society of Nephrology. Abbreviations PA=Primary Hyperaldosteronism CVD=Cardiovascular Disease PAPY=Primary Aldosteronism Prevalence in Hypertension APA=Aldosterone-Producing Adenoma BAH=Bilateral Adrenal Hyperplasia ARR=Aldosterone Renin Ratio AF=Atrial Fibrillation OSA=Obstructive Sleep Apnea OR=Odds Ratio AHI=Apnea Hypopnea Index ABP=Ambulatory Blood Pressure AVS=Adrenal Vein Sampling CT=Computerized Tomography MRI=Magnetic Resonance Imaging SIT=Sodium Infusion Test FST=Fludrocortisone Suppression Test CCT=Captopril Challenge Test PAC=Plasma Aldosterone Concentration PRA=Plasma Renin Activity MRA=Mineralocorticoid Receptor Antagonist MR=Mineralocorticoid Receptor 2 Abstract Nearly seven decades have elapsed since the clinical and biochemical features of Primary Hyperaldosteronism (PA) were described by Conn. PA is now widely recognized as the most common form of secondary hypertension. PA has a strong correlation with cardiovascular disease and failure to recognize and/or properly diagnose this condition has profound health consequences. With proper identification and management, PA has the potential to be surgically cured in a proportion of affected individuals. The diagnostic pursuit for PA is not a simplistic endeavor, particularly since an enhanced understanding of the disease process is continually redefining the diagnostic and treatment algorithm.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Mineralocorticoid Receptor Blockers for Moderate Kidney Dysfunction: More Merit Than Ever?
    Hypertension Research (2021) 44:1352–1354 https://doi.org/10.1038/s41440-021-00690-6 COMMENT Mineralocorticoid receptor blockers for moderate kidney dysfunction: more merit than ever? 1 1 1 Masashi Mukoyama ● Takashige Kuwabara ● Masataka Adachi Received: 28 May 2021 / Accepted: 31 May 2021 / Published online: 15 July 2021 © The Japanese Society of Hypertension 2021 Mineralocorticoid receptor (MR) antagonists, such as spir- MR activity with high specificity. To date, several clinical onolactone and eplerenone, are currently used to treat studies have been performed to evaluate its effects [4–6], hypertension and chronic heart failure. MR antagonists act which revealed effective blood pressure reduction with rela- on MRs expressed in the distal tubules of the kidney, tively few adverse events, including hyperkalemia (Table 1). including distal convoluted tubules, connecting tubules and In addition, esaxerenone can further reduce urinary albumin the cortical collecting duct, thereby promoting sodium excretion in addition to RAS inhibitors without significantly excretion without the loss of potassium into the urine [1]. affecting renal function [6]. Finerenone, a second nonsteroidal MR antagonists may be effective for the treatment of low- MR blocker for which large-scale clinical trials have been 1234567890();,: 1234567890();,: renin hypertension and are preferentially used for the completed [7, 8], showed a lower risk of CKD progression treatment of primary aldosteronism; furthermore, in patients and cardiovascular events than placebo in patients with CKD with resistant hypertension, additional administration at a and type 2 diabetes (Table 1). Based on these results, much low to moderate dose (spironolactone, 25–50 mg/day) may attention has been given to novel MR blockers as promising further decrease blood pressure [2].
    [Show full text]
  • The Role of Aldosterone Inhibitors on Cardiac Ischemia/Reperfusion Injury
    Canadian Journal of Physiology and Pharmacology THE ROLE OF ALDOSTERONE INHIBITORS ON CARDIAC ISCHEMIA/REPERFUSION INJURY Journal: Canadian Journal of Physiology and Pharmacology Manuscript ID cjpp-2020-0276.R1 Manuscript Type: Review Date Submitted by the 16-Jul-2020 Author: Complete List of Authors: Dragasevic, Nevena; University of Kragujevac, Faculty of Medical Sciences, Department of Physiology, Svetozara Markovica 69, 34 000 Kragujevac, Serbia JAKOVLJEVIC, Vladimir; University of Kragujevac, Faculty of Medical Sciences, DepartmentDraft of Physiology, Svetozara Markovica 69, 34 000 Kragujevac, Serbia, Department of Physiology; 1st Moscow State Medical University IM Sechenov, Moscow, Russian Federation, Department of Human Pathology Zivkovic, Vladimir; University of Kragujevac, Faculty of Medical Sciences, Department of Physiology, Svetozara Markovica 69, 34 000 Kragujevac, Serbia Draginic, Nevena; University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, Svetozara Markovica 69, 34 000 Kragujevac, Serbia Andjic, Marijana; University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, Svetozara Markovica 69, 34 000 Kragujevac, Serbia Bolevich, Sergey; University IM Sechenov, 1st Moscow State Medical,Trubetskaya street 8, 119991 Moscow, Department of Human Pathology Jovic, Slavoljub; University of Belgrade, Department of Physiology and Biochemistry, Faculty of Veterinary Medicine, Bul. Oslobodjenja 18, Belgrade, Serbia Is the invited manuscript for consideration in a Special Joint North American/European
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Report on the Deliberation Results December 4, 2018 Pharmaceutical
    Report on the Deliberation Results December 4, 2018 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare Brand Name Minnebro Tablets 1.25 mg Minnebro Tablets 2.5 mg Minnebro Tablets 5 mg Non-proprietary Name Esaxerenone (JAN*) Applicant Daiichi Sankyo Company, Limited Date of Application February 26, 2018 Results of Deliberation In its meeting held on December 3, 2018, the First Committee on New Drugs concluded that the product may be approved and that this result should be presented to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The product is not classified as a biological product or a specified biological product. The re-examination period is 8 years. Neither the drug product nor its drug substance is classified as a poisonous drug or a powerful drug. Condition of Approval The applicant is required to develop and appropriately implement a risk management plan. *Japanese Accepted Name (modified INN) This English translation of this Japanese review report is intended to serve as reference material made available for the convenience of users. In the event of any inconsistency between the Japanese original and this English translation, the Japanese original shall take precedence. PMDA will not be responsible for any consequence resulting from the use of this reference English translation. Review Report November 12, 2018 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical product submitted for marketing approval conducted by the Pharmaceuticals and Medical Devices Agency (PMDA). Brand Name Minnebro Tablets 1.25 mg Minnebro Tablets 2.5 mg Minnebro Tablets 5 mg Non-proprietary Name Esaxerenone Applicant Daiichi Sankyo Company, Limited Date of Application February 26, 2018 Dosage Form/Strength Each tablet contains 1.25 mg, 2.5 mg, or 5 mg of Esaxerenone.
    [Show full text]
  • Esaxerenone: First Global Approval
    Drugs https://doi.org/10.1007/s40265-019-01073-5 ADISINSIGHT REPORT Esaxerenone: First Global Approval Sean Duggan1 © Springer Nature Switzerland AG 2019 Abstract Esaxerenone (MINNEBRO™)—a novel oral, non-steroidal, selective mineralocorticoid receptor blocker—is being developed by Daiichi Sankyo for the treatment of hypertension and diabetic nephropathies. In January 2019, based on positive results from a phase III trial conducted in Japan in patients with essential hypertension, esaxerenone received marketing approval in Japan for the treatment of hypertension. This article summarizes the milestones in the development of esaxerenone leading to this frst global approval for the treatment of hypertension. 1 Introduction 1.1 Company Agreements Daiichi Sankyo are developing esaxerenone (MINNE- In March 2006, Sankyo Co., Ltd, a subsidiary of Daiichi BRO™), a novel oral, non-steroidal, selective mineralocor- Sankyo, entered into a research collaboration agreement ticoid receptor blocker, for the treatment of hypertension and with Exelixis Inc. to develop and commercialise novel ther- diabetic nephropathies. Excessive mineralocorticoid recep- apies targeting the mineralocorticoid receptor [7]. Daiichi tor activation by endogenous ligands such as aldosterone has Sankyo obtained an exclusive, worldwide licence to certain been shown to play an important role in the development of intellectual property primarily relating to compounds that hypertension, as well as progression of nephropathy and car- modulate the mineralocorticoid receptor, including esaxer- diovascular disease [1–4]. Esaxerenone is thought to exert an enone [7, 8]. After completion of the research term, Sankyo antihypertensive efect by blocking mineralocorticoid recep- Co., Ltd has assumed responsibility for all further clinical tor activation. Esaxerenone was approved in Japan for the and regulatory development of the drug.
    [Show full text]
  • Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker
    biomedicines Article Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker Wei-Ting Chang 1,2,3 and Sheng-Nan Wu 4,5,* 1 Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan 71005, Taiwan; [email protected] 2 Division of Cardiovascular Medicine, Chi-Mei Medical Center, Tainan 71004, Taiwan 3 Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan 4 Department of Physiology, National Cheng Kung University Medical College, Tainan 70101, Taiwan 5 Institute of Basic Medical Sciences, National Cheng Kung University Medical College, Tainan 70101, Taiwan * Correspondence: [email protected]; Tel.: +886-6-2353535 (ext. 5334); Fax: +886-6-2362780 Abstract: Esaxerenone (ESAX; CS-3150, Minnebro®) is known to be a newly non-steroidal min- eralocorticoid receptor (MR) antagonist. However, its modulatory actions on different types of ionic currents in electrically excitable cells remain largely unanswered. The present investigations were undertaken to explore the possible perturbations of ESAX on the transient, late and persistent + components of voltage-gated Na current (INa) identified from pituitary GH3 or MMQ cells. GH3- cell exposure to ESAX depressed the transient and late components of INa with varying potencies. The IC50 value of ESAX required for its differential reduction in peak or late INa in GH3 cells was Citation: Chang, W.-T.; Wu, S.-N. estimated to be 13.2 or 3.2 µM, respectively. The steady-state activation curve of peak INa remained Characterization of Direct unchanged during exposure to ESAX; however, recovery of peak INa block was prolonged in the Perturbations on Voltage-Gated presence 3 µM ESAX.
    [Show full text]
  • Daiichi Sankyo Group Value Report 2017
    Daiichi Sankyo Group Value Report 2017 Daiichi Sankyo Group Value Daiichi Sankyo Group Value Report 2017 Contents Messages from the CEO & the COO 02 Highlights of Value Report 2017 Our Mission 06 Daiichi Sankyo’s Strengths 08 Major Accomplishments in Fiscal 2016 10 Daiichi Sankyo’s Value Creation Process 12 5-Year Business Plan (FY2016 - FY2020) History of Daiichi Sankyo 14 Transformation 2025 Vision and 5-Year Business Plan 18 DS — A Bridge to Tomorrow 2025 Vision 20 5-Year Business Plan and its Progress 21 Operations and Financial Position 48 The Daiichi Sankyo Group’s Value Chain and Organization 52 P02-05 P08-09 P21-47 Global Management Structure 54 Business Activities Messages from the CEO & Daiichi Sankyo’s Strengths 5-Year Business Plan and the COO its Progress Business Units Here, you will find messages from This section explains the Daiichi Sankyo This section looks at the strategic targets ・ Sales & Marketing Unit 56 Chairman and CEO George Nakayama Group’s unique strengths, namely Science set forth for accomplishing the goals of the ・ Sales & Marketing Unit: Daiichi Sankyo Espha Co., Ltd. 57 on the management practices that take & Technology, Global Organization & 5-year business plan, progress toward advantage of the Group’s strengths and Talent, and Presence in Japan. these targets, and the initiatives that will ・ Vaccine Business Unit 58 from President and COO Sunao Manabe on be implemented in the future. ・ Daiichi Sankyo Healthcare Co., Ltd. 59 the Group’s initiatives for accomplishing the goals of the 5-year business plan. ・ Daiichi Sankyo, Inc.(DSAC) 60 ・ Luitpold Pharmaceuticals, Inc.
    [Show full text]
  • The 2020 Italian Society of Arterial Hypertension (SIIA) Practical Guidelines for the Management of Primary Aldosteronism
    International Journal of Cardiology Hypertension 5 (2020) 100029 Contents lists available at ScienceDirect International Journal of Cardiology Hypertension journal homepage: www.journals.elsevier.com/international-journal-of-cardiology-hypertension/ Review Article The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism Gian Paolo Rossi a,*, Valeria Bisogni a, Alessandra Violet Bacca b, Anna Belfiore c, Maurizio Cesari a, Antonio Concistre d, Rita Del Pinto e, Bruno Fabris f, Francesco Fallo g, Cristiano Fava h, Claudio Ferri e, Gilberta Giacchetti i, Guido Grassi j, Claudio Letizia d, Mauro Maccario k, Francesca Mallamaci l, Giuseppe Maiolino a, Dario Manfellotto m, Pietro Minuz h, Silvia Monticone n, Alberto Morganti o, Maria Lorenza Muiesan p, Paolo Mulatero n, Aurelio Negro q, Gianfranco Parati r, Martino F. Pengo r, Luigi Petramala d, Francesca Pizzolo h, Damiano Rizzoni p, Giacomo Rossitto a,s, Franco Veglio n, Teresa Maria Seccia a a Clinica dell'Ipertensione Arteriosa, Department of Medicine - DIMED, University of Padua, Italy b Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy c Clinica Medica "A. Murri", Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy d Department of Translational and Precision Medicine, Unit of Secondary Arterial Hypertension, "Sapienza" University of Rome, Italy e University of L'Aquila, Department of Life, Health and Environmental Sciences, San Salvatore Hospital, L'Aquila, Italy f Department of Medical Sciences, Universita degli Studi di Trieste, Cattinara Teaching Hospital, Trieste, Italy g Department of Medicine, DIMED, Internal Medicine 3, University of Padua, Italy h Department of Medicine, University of Verona, Policlinico "G.B.
    [Show full text]
  • Diabetics Could Boost Daiichi's Nascent Heart Asset
    September 26, 2017 Diabetics could boost Daiichi's nascent heart asset Amy Brown Daiichi Sankyo has revealed a phase III win with esaxerenone in hypertension, a project that many years ago emerged from the labs of Exelixis. If all goes well the asset could develop into a helpful revenue generator for both groups – the Japanese giant is struggling with patent expiries, and the US developer is in the midst of launching its oncology franchise. Esaxerenone works in a similar way to Pfizer’s long-expired Inspra, although presumably it has some pharmacological advantages – the pivotal trial pitted the two agents head to head. At the same time Daiichi announced a move into diabetic nephropathy, where Bayer is already active with another similar compound, and representing an area that arguably holds greater commercial potential. That Bayer project is finerenone, which like esaxerenone prevents binding of aldosterone by blocking the mineralocorticoid receptor and helping to control a rise in blood pressure. Like other next-generation antagonists in development it is described as non-steroidal, and has been designed for greater selectivity towards the mineralocorticoid receptor than Inspra plus stronger binding affinity. As such, it is hoped that these newer agents will be more tolerable than earlier compounds like eplerenone, Inspra's active ingredient. Fear of hyperkalaemia, caused by very high potassium levels, has severely restricted the use of Inspra, despite evidence that the drug can reduce mortality and morbidity in patients with heart failure. That potential remains to be proven, however, and limited detail released by Daiichi on the Esax-HTN study leaves the question unanswered for now.
    [Show full text]
  • Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
    pharmaceuticals Review Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease Nina Vodošek Hojs 1,* , Sebastjan Bevc 1,2, Robert Ekart 2,3 , Nejc Piko 3 , Tadej Petreski 1,2 and Radovan Hojs 1,2 1 Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia; [email protected] (S.B.); [email protected] (T.P.); [email protected] (R.H.) 2 Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia; [email protected] 3 Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +386-41-366-133; Fax: +386-2-321-28-45 Abstract: Diabetes mellitus is a global health issue and main cause of chronic kidney disease. Both diseases are also linked through high cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) is present in up to 40% of diabetic patients; therefore, prevention and treatment of DKD are of utmost importance. Much research has been dedicated to the optimization of DKD treatment. In the last few years, mineralocorticoid receptor antagonists (MRA) have experienced a renaissance in this field with the development of non-steroidal MRA. Steroidal MRA have known cardiorenal benefits, but their use is limited by side effects, especially hyperkalemia. Non-steroidal MRA still block the damaging effects of mineralocorticoid receptor overactivation (extracellular fluid volume expansion, inflammation, fibrosis), but with fewer side effects (hormonal, hyperkalemia) Citation: Vodošek Hojs, N.; Bevc, S.; than steroidal MRA. This review article summarizes the current knowledge and newer research Ekart, R.; Piko, N.; Petreski, T.; Hojs, conducted on MRA in DKD.
    [Show full text]